The takeaway
Unicycive Therapeutics Inc shows a pronounced seasonal pattern over 5 years of data — strongest in September (+5.7%) and softest in June (−21.3%).
Right now
In July, the stock has fallen 20% of years, averaging −16.7%, roughly 18.8 pts behind the S&P 500.
The full picture
Unicycive Therapeutics Inc's most dependable month has been September, higher in 4 of 5 years; June has been its least reliable, up just 0% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | — | — | — | — | — | — |
Month by month
The stock's clearest edge over the S&P 500 lands in March (+75.0 pts); it has trailed the market most in June (−21.5 pts).
“vs S&P” is Unicycive Therapeutics Inc’s average for a month minus the S&P 500’s average for that same month — isolating Unicycive Therapeutics Inc’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, September has closed higher 80% of the time versus 80% across the last 5 years — the pattern is holding.
Figures are the typical (median) September return and how often it rose — the last 5 years versus the last 5(the heatmap’s default window). This verdict stays anchored to that 5-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Strip the year back and a single month does the heavy lifting: September, up in 4 of 5 Septembers while the other eleven tend to blur together.
The headline flatters a touch — its +5.7% average sits well above the +2.2% a typical year delivers, the work of a few big Septembers. It is among its calmest months, too, its returns swinging least from year to year (a 12.8% spread). Crucially, the gain is the stock's own rather than a rising tide's: September has cleared the S&P 500 by +5.8 points above the index. It bucks the broad tape, besides: September lifts just 39% of stocks across the market.
The strength clusters rather than stands alone — September–December forms a firm stretch that carries much of the year. The weaker half of the year is plainer: June has been the soft spot — the weakest of 6 months that average a loss (−21.3%), and the edge isn't year-round — the stock has trailed the S&P 500 in June, April, and July. Its roughest month on record was a −44.8% July in 2021 — a reminder of how hard even a seasonal name can fall.
The takeaway is less about when to buy than what to expect: September aside, the stock's months offer little reliable tilt. With a short 5-year record and returns that swing hard year to year, the signal is best held loosely.
Short answers on the stock's best month (September), its worst (June), and whether it really trades seasonally.
Yes, to a pronounced degree. Since 2021 its best month (September, +5.7%) has run well ahead of its worst (June, −21.3%) — the heatmap above shows how steady that gap has been year to year.
September has been the strongest, averaging +5.7% and closing higher in 4 of 5 years since 2021.
It's the weakest, averaging −21.3% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade